A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients

Published:2001-05 Issue:8 Volume:37 Page:1006-1013
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zori Comba A.,Blajman C.,Richardet E.,Bella S.,Vilanova M.,Cóppola F.,Van Kooten M.,Rodger J.,Giglio R.,Balbiani L.,Perazzo F.,Montiel M.,Chacón M.,Pujol F.,Mickiewicz E.,Cazap E.,Recondo G.,Lastiri F.,Simon J.,Wasserman E.,Schmilovich A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Epidemiologic panorama of colorectal cancer in Mexico, 1980–1993;Tovar-Guzman;Dis. Colon Rectum,1998

2. Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil;Falcone;Ann. Oncol.,1994

3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer;J. Clin. Oncol.,1998

4. Standard dose (Mayo Regimen) 5-fluorouracil and low dose folinic acid;Tomiak;Am. J. Clin. Oncol.,2000

5. Raymond E, Chaney S, Taamma A, et al. Preclinical and clinical studies of oxaliplatin. Ann Oncol 1998; 1053–1071.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of chemosensitizing agents of colorectal cancer in Rauvolfia vomitoria using an NMR-based chemometric approach;Frontiers in Chemistry;2023-01-06

2. Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer;Pharmaceutics;2020-02-23

3. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer;Expert Review of Anticancer Therapy;2015-10-27

4. Issues in the assessment of non-inferiority: perspectives drawn from case studies;Pharmaceutical Statistics;2011-09

5. Therapeutic effectiveness of slow-release PLGA-oxaliplatin microsphere on human colorectal tumor-bearing mice;Anti-Cancer Drugs;2010-07